Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. UroGen Pharma's Average Total Inventories for the quarter that ended in Dec. 2023 was $5.34 Mil. UroGen Pharma's Revenue for the
three
months ended in Dec. 2023 was $23.53 Mil.
UroGen Pharma's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.23.
UroGen Pharma's Inventory-to-Revenue for the quarter that ended in Dec. 2023
declined
from Sep. 2023 (0.24) to Sep. 2023 (0.23)
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
UroGen Pharma's Days Inventory for the
three
months ended in Dec. 2023 was 213.06.
Inventory Turnover measures how fast the company turns over its inventory within a year.
UroGen Pharma's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.43.
UroGen Pharma Inventory-to-Revenue Historical Data
The historical data trend for UroGen Pharma's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of UroGen Pharma's Inventory-to-Revenue
For the Biotechnology subindustry, UroGen Pharma's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Inventory-to-Revenue falls into.
UroGen Pharma Inventory-to-Revenue Calculation
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
UroGen Pharma's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
UroGen Pharma's Days Inventory for the
three
months ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of UroGen Pharma's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
UroGen Pharma (UroGen Pharma) Business Description
UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
URGN has been successfully added to your 